You know your patients and their families better than most doctors. But family history alone isn’t enough to determine a woman's risk of cancer. Comprehensive risk assessment and genetic testing for all women helps you identify those who may need additional health care.1
Genetic cancer screening can help you uncover a women’s hereditary health risk before you find a lump
1 in 4 women in the general population meet criteria for hereditary cancer genetic testing.2
- Nearly half of patients with a BRCA1 or BRCA2 genetic variant do not have a suggestive family history—but need additional care3
- Cancer risk doesn’t end with a negative genetic test report. A Tyrer-Cuzick score can be included with results to help you personalize a screening plan.*
You can give women a better chance at identifying cancer early or preventing it altogether with genetic testing
Early identification through genetic testing may lead to improved outcomes for women. For patients with BRCA1 or BRCA2 variants, knowing their genetic status before a breast cancer diagnosis leads to improved survival rates.4
For those patients who test negative for pathogenic variants, Invitae can provide a Tyrer-Cuzick score, so you can get a more complete picture.
5-year survival rates improve when patients know their BRCA status
5-year survival rates improve when patients know their BRCA status
The 5-year survival rate in patients who knew their BRCA1/BRCA2 status before diagnosis is 94% compared with 78% in patients who only found out their status after diagnosis (P<0.03).4
